CagriSema
A weekly combo shot of cagrilintide (amylin) and semaglutide (GLP-1). In phase 3 trials, adults with obesity lost about 20% of body weight on average.
- Evidence
- Ongoing clinical research
- Half-life
- ~7 days
- Sources
- 3 cited
Is cagriSema FDA-approved?
Investigational. Not FDA-approved.
Overview
CagriSema pairs two fullness signals in one weekly shot. In the 68-week REDEFINE 1 trial in adults with obesity, average weight loss was 20.4% versus 3.0% on placebo. In REDEFINE 2, in people with obesity and type 2 diabetes, it was 13.7% versus 3.4%. Stomach side effects were common.
How it works
Semaglutide works on GLP-1 receptors; cagrilintide works on amylin receptors. The two pathways add up, so the combo produces more weight loss than either one alone.
How long does cagriSema stay in the body?
Both parts last about a week in the body, so it's taken once weekly.
What it's studied for
- Obesity
- Type 2 diabetes
- Heart outcomes
Reported side effects
- Nausea, vomiting, diarrhea, constipation (about 80% had some stomach side effect in REDEFINE 1)
Related: Cagrilintide, Survodutide, Retatrutide, Mazdutide.
Sources
The studies and prescribing labels this page is written from.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med, 2025 PubMed
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med, 2025 PubMed
- Cagrilintide with semaglutide in type 2 diabetes: a phase 2 trial. Lancet, 2023 PubMed
